Immuneering Corporation has released a corporate presentation focusing on their efforts to help cancer patients outlive their disease. The company is prioritizing durability and tolerability in their approach, aiming for longer patient survival with minimized adverse events. Their initial focus is on a Phase 2a trial for atebimetinib (IMM-1-104) combined with modified Gemcitabine and nab-Paclitaxel (mGnP) for first-line pancreatic cancer. The presentation highlights an impressive 94% 6-month overall survival rate for patients treated with this combination, based on interim data from an ongoing trial. The median overall survival has not been reached, indicating promising potential outcomes. You can access the full presentation through the link below.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。